JMJames D. Murphy

James D. Murphy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James D. Murphy has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Albert C. Koong

    Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

    1 shared publication
  • Daniel T. Chang

    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California

    1 shared publication
  • Heidi N. Yeung

    Department of Palliative Care, Stanford University School of Medicine, Stanford, California

    1 shared publication
  • Jon Abelson

    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California

    1 shared publication
  • Lorene M. Nelson

    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California

    1 shared publication
  • Megan E. Daly

    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California

    1 shared publication

Latest Publications

  • Cost‐effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer

    by James D. Murphy, Daniel T. Chang, Jon Abelson, Megan E. Daly, Heidi N. Yeung, Lorene M. Nelson, Albert C. Koong

    BACKGROUND: Radiotherapy may improve the outcome of patients with pancreatic cancer but at an increased cost. In this study, the authors evaluated the cost‐effectiveness of modern radiotherapy techniques in the treatment of locally advanced pancreatic cancer.METHODS: A Markov decision‐analytic model was constructed to compare the cost‐effectiveness of 4 treatment regimens: gemcitabine alone, gemcitabine plus conventional radiotherapy, gemcitabine plus intensity‐modulated radiotherapy (IMRT); and gemcitabine with stereotactic body radiotherapy (SBRT). Patients transitioned between the following 5 health states: stable disease, local progression, distant failure, local and distant failure, and death. Health utility tolls were assessed for radiotherapy and chemotherapy treatments and for radiation toxicity.RESULTS: SBRT increased life expectancy by 0.20 quality‐adjusted life years (QALY) at an increased cost of $13,700 compared with gemcitabine alone (incremental cost‐effectiveness ratio [ICER] = $69,500 per QALY). SBRT was more effective and less costly than conventional radiotherapy and IMRT. An analysis that excluded SBRT demonstrated that conventional radiotherapy had an ICER of $126,800 per QALY compared with gemcitabine alone, and IMRT had an ICER of $1,584,100 per QALY compared with conventional radiotherapy. A probabilistic sensitivity analysis demonstrated that the probability of cost‐effectiveness at a willingness to pay of $50,000 per QALY was 78% for gemcitabine alone, 21% for SBRT, 1.4% for conventional radiotherapy, and 0.01% for IMRT. At a willingness to pay of $200,000 per QALY, the probability of cost‐effectiveness was 73% for SBRT, 20% for conventional radiotherapy, 7% for gemcitabine alone, and 0.7% for IMRT.CONCLUSIONS: The current results indicated that IMRT in locally advanced pancreatic cancer exceeds what society considers cost‐effective. In contrast, combining gemcitabine with SBRT increased clinical effectiveness beyond that of gemcitabine alone at a cost potentially acceptable by today's standards. Cancer 2012;. © 2011 American Cancer Society.